Company intelligence / Profile preview

Traverse Biosciences

Stony Brook, New York, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

TRB-N0224 is envisioned as the first FDA-approved, once-daily edible prescription medication for the prevention and control of canine periodontal disease, with annual sales expected to exceed $100M in the US alone

Therapeutic areas: Other
Modalities: Small molecule
Industry: Veterinary

Partnerships

Aratana Therapeutics (development agreement executed in 2015 for advancement of TRB-N0224)

Beyond the preview

Go deeper on Traverse Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Traverse Biosciences.

Explore the full profile